Nearly all of patients with chronic myeloid leukemia (CML) and 20–30% of patients with acute lymphoblastic leukemia (ALL) have BCR–ABL1 gene fusions, which are the driving molecular abnormality of these diseases. This evidence concerns the gene BCR and acute lymphoblastic leukemia.